Cara Therapeutics Inc. (CARA Quick QuoteCARA - Free Report) was a big mover last session, as the company saw its shares rise almost 6% on the day. The upside came on the company’s announcement of the successful initiation of the phase IIb clinical trial of its oral formulation of CR845 for the treatment of pain associated with osteoarthritis. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.32 to $6.50 in the past one-month time frame.

In the last 30 days, the company has seen one downward estimate revision and the Zacks Consensus Estimate also moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.      

Cara Therapeutics currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is 0.00%.

CARA THERAPEUTC Price

 

CARA THERAPEUTC Price | CARA THERAPEUTC Quote

A better-ranked Medical/Biomedical-Gene stock is ANI Pharmaceuticals, Inc. (ANIP Quick QuoteANIP - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CARA going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>